#### DEPARTMENT OF HEALTH AND HUMAN SERVICES FOOD AND DRUG ADMINISTRATION DISTRICT ADDRESS AND PHONE NUMBER DATE(S) OF INSPECTION 10903 New Hampshire Avenue 04/20/2015 - 04/24/2015 Silver Spring, MD 20993 (301) 594-4695 Fax: (301) 594-4715 3002807795 Industry Information: www.fda.gov/oc/industry TO: Akihiro Okubo, President and Representative Director STREET ADDRESS 2951 Ishikawa-Cho Olympus Medical Systems Corporation TYPE ESTABLISHMENT HISPECTED CITY STATE ZIP CODE COUNTRY Hachioji-Shi 192-8507, Specification Developer/Headquarters Japan

This document lists observations made by the FDA representative(s) during the inspection of your facility. They are inspectional observations, and do not represent a final Agency determination regarding your compliance. If you have an objection regarding an observation, or have implemented, or plan to implement, corrective action in response to an observation, you may discuss the objection or action with the FDA representative(s) during the inspection or submit this information to FDA at the address above. If you have any questions, please contact FDA at the phone number and address above.

The observations noted in this Form FDA-483 are not an exhaustive listing of objectionable conditions. Under the law, your firm is responsible for conducting internal self-audits to identify and correct any and all violations of the quality system requirements.

# DURING AN INSPECTION OF YOUR FIRM WE OBSERVED:

### OBSERVATION 1

An MDR report was not submitted within 30 days of receiving or otherwise becoming aware of information that reasonably suggests that a marketed device may have caused or contributed to a death or serious injury.

Specifically (b) Medical Device Reports (MDR's) were reported late by Olympus Medical Systems Corporation (OMSC) specific to the TJF-Q180V duodenoscope related to infection/contamination. January 1, 2010 to March 31, 2015. The TJF-Q180V duodenoscope is the same model that is sold in United States. OMSC is responsible for international complaints requiring MDR submission to FDA. The following are three examples of the (b) provided by the firm for late submission.

MDR#	Date Aware	Date Submitted to FDA	Days Late
8010047-2015-00210	11/21/2013	3/16/2015	450
8010047-2015-00218	4/26/2012	3/13/2015	1021
8010047-2015-00282	6/12/2014	3/31/2015	262

## **OBSERVATION 2**

Corrective and preventive action activities and/or results have not been adequately documented.

Specifically. Olympus Medical Systems Corporation (OMSC) conducted a review of Medical Device Reporting (MDR). OSMC's review required the correction of MDRs that were incorrectly submitted where multiple patient complaints were under one MDR. The TJF-Q180V duodenoscope related to infection/contamination was identified in these MDRs and is the same model that is sold in the United States. MDRs 8010047-2015-00216 through 8010047-2015-00230 and 8010047-2015-00232 through 8010047-2015-00237 was submitted on 3/13/2015 as a corrective action without generating a Corrective and Preventive Action (CAPA).

SEE REVERSE Stephen C. Smith, Investigator Hope Sanita			DATE ISSUED
	SEE REVERSE OF THIS PAGE	Stephen C. Smith, Investigator Hyplen & Smith Maida Henesian, Investigator Mail Henesian	

FORM FDA 483 (09/08) PREVIOUS EDITION OBSOLETE INSPECTIONAL OBSERVATIONS PAGE 1 OF 2 PAGES

DEPARTMENT OF HEALTH AND HUMAN SERVICES FOOD AND DRUG ADMINISTRATION DISTRICT ADDRESS AND PHONE NUMBER DATE(S) OF INSPECTION 10903 New Hampshire Avenue 04/20/2015 - 04/24/2015 FEI NUMBER Silver Spring, MD 20993 (301) 594-4695 Fax: (301) 594-4715 3002807795 Industry Information: www.fda.gov/oc/industry TO: Akihiro Okubo, President and Representative Director STREET ADDRESS Olympus Medical Systems Corporation CHTY STATE ZP CODE COUNTRY 2951 Ishikawa-Cho TYPE ESTABLISHMENT INSPECTED Hachioji-Shi 192-8507, Specification Developer/Headquarters Japan

# **Observation Annotations**

Observation 1:

Promised to correct.

Observation 2:

Promised to correct.

SEE REVERSE
OF THIS PAGE

Stephen C. Smith, Investigator Mylen C Su 4

Maida Henesian, Investigator Atic C Sin 40

04/24/2015

FORM FDA 483 (09/08)

PREVIOUS EDITION OBSOLETE

INSPECTIONAL OBSERVATIONS

PAGE 2 OF 2 PAGES